Filter by: patients
What is Sativex?

Sativex is a mouth spray developed for multiple sclerosis patients, who can use it to alleviate neuropathic pain and spasticity. It is distinct from all other pharmaceutically produced cannabinoids currently available because it is derived from botanical material, rather than a synthetic process.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Pain 5 1 Efficacy_moderate
Other 2 1 Efficacy_major
relief of nerologic pain 1 0
Facial pain 1 0

See all 7 patients currently taking Sativex

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
1
Mild
0
None
1

Commonly reported side effects, conditions, and hospitalizations associated with Sativex

Fainting 1

Reported Dosages

  0 as needed 3other as needed 5.5ml as needed 1.2 mcg daily 2 other daily 6 daily 40 g daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Sativex (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other 2   Other: 100%
Expense 1   Expense: 50%

See all 2 patients who’ve stopped taking Sativex

Currently Taking Sativex

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Sativex

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Sativex

Always
0 0%
Usually
1 50%
Sometimes
1 50%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Sativex

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
2 100%

Cost

Paid out of pocket

Cost of Sativex

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 100%

Report created on February 11, 2012.